Efficacy of repeated intravitreal Lucentis (Ranibizumab) injection according to the genotypic characteristics of exudative age-related macular degeneration in Koreans
Not Applicable
Completed
- Conditions
- Diseases of the eye and adnexa
- Registration Number
- KCT0002531
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
1. An age over 50 years
2. Exudative age-related macular degeneration patients with subfoveal leakage on fluorescein angiogram (FA) and exudative change on OCT who are treated with intravitreal anti-VEGF injections
3. Agreement to genetic analysis
Exclusion Criteria
1. any previous treatment for exudative age-related macular degeneration such as laser photocoagulation, PDT, or anti-VEGF injection; 2. other concomitant ocular disease such as diabetic retinopathy, retinal vascular disease, epiretinal membrane, and high myopia; 3. previous vitreoretinal surgery; and (4) presence of a disciform macular scar or atrophy.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of central macular thickness
- Secondary Outcome Measures
Name Time Method Genotypic association with visual and anatomic outcome measures